ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

All Content

This video highlights emerging data on genomic markers of response to neoadjuvant chemotherapy for patients with bladder cancer.

In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.

Adolescents and young adults with leukemia experienced inferior outcomes compared with children, especially if they were treated outside of a specialized cancer center.

Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy, according to a retrospective, non-randomized study.

This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.

A single cycle of adjuvant bleomycin, etoposide, and cisplatin (BEP) chemotherapy might reduce recurrence rates for nonseminomatous or combined germ cell tumors of the testis.

This video examines the results of a study that looked at the prognostic value of androgen receptor full-length detection using a CTC-based mRNA assay in metastatic castration-resistant prostate cancer starting treatment with the AR-targeted agents.

The identification of ugly duckling nevi using a whole-body skin examination for intrapatient comparative analysis improves accuracy of melanoma detection.

Intravesical rAd-IFNα/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.

Pembrolizumab is associated with longer overall survival and fewer treatment-related toxicities vs chemotherapy for patients with advanced urothelial carcinoma.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.